DBV Technologies (DBVT) to Release Quarterly Earnings on Wednesday

DBV Technologies (NASDAQ:DBVT) is projected to issue its Q4 2025 results before the market opens on Wednesday, April 29th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $1.0010 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, April 2, 2026 at 7:00 AM ET.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Saturday, February 14th. The company reported ($1.15) earnings per share (EPS) for the quarter. DBV Technologies had a negative return on equity of 189.17% and a negative net margin of 2,606.83%.The business had revenue of $0.65 million for the quarter. On average, analysts expect DBV Technologies to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

DBV Technologies Stock Performance

NASDAQ DBVT opened at $19.80 on Monday. The business’s 50 day moving average is $20.90 and its two-hundred day moving average is $18.75. DBV Technologies has a 12-month low of $7.53 and a 12-month high of $26.18. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -3.79 and a beta of -0.94.

Institutional Investors Weigh In On DBV Technologies

Institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada acquired a new stake in shares of DBV Technologies in the 4th quarter worth approximately $34,000. Truvestments Capital LLC lifted its stake in DBV Technologies by 71.3% in the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after buying an additional 1,620 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in DBV Technologies in the 4th quarter valued at approximately $115,000. Two Sigma Investments LP purchased a new stake in DBV Technologies in the 3rd quarter valued at approximately $167,000. Finally, Citadel Advisors LLC purchased a new stake in DBV Technologies in the 3rd quarter valued at approximately $220,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

Analysts Set New Price Targets

DBVT has been the topic of several recent analyst reports. Citizens Jmp boosted their target price on DBV Technologies from $45.00 to $47.00 and gave the stock a “market outperform” rating in a research report on Friday, March 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a research report on Monday, December 29th. Guggenheim restated a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a report on Friday, March 27th. Finally, Wall Street Zen cut DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.65.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.